Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
AssigneesZycos Inc., a Delaware corporation, King's College London, an institution incorporated by Royal Charter in England
InventorsMark Peakman, Roman M. Chicz
Life of this patent
Estimating the term…
Abstract
The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.
Claims2
An isolated peptide less than 26 amino acid residues in length, comprising a sequence KVESSPSRSDY (SEQ ID NO:52).
Dependencies are inferred from the claim text.